Kymera Therapeutics, Inc. (NASDAQ:KYMR) Holdings Boosted by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 11.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 453,377 shares of the company’s stock after buying an additional 47,507 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Kymera Therapeutics were worth $21,458,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KYMR. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the period. Comerica Bank boosted its stake in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at $139,000. Finally, Virtu Financial LLC acquired a new stake in shares of Kymera Therapeutics during the 1st quarter valued at $207,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on KYMR shares. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Guggenheim raised their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. UBS Group dropped their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Wells Fargo & Company lifted their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, Stephens assumed coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $52.13.

Insider Activity at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Up 4.5 %

NASDAQ KYMR opened at $47.02 on Tuesday. The stock has a market cap of $3.05 billion, a P/E ratio of -20.09 and a beta of 2.21. The company’s 50-day simple moving average is $46.94 and its 200 day simple moving average is $41.98. Kymera Therapeutics, Inc. has a twelve month low of $18.89 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.